Following a transformative year in 2025, marked by validation of its PROBODY masking platform, CytomX Therapeutics Inc. (CTMX) is positioning its two clinical-stage programs for key upcoming data readouts.
The company's PROBODY therapeutic platform is designed to enable a more targeted approach to cancer treatment. PROBODY therapeutics are engineered to bind preferentially to tumor tissue while limiting activity in healthy tissue. This selectivity is achieved through a proprietary masking mechanism that temporarily blocks the therapy's target-binding region, thereby reducing activity in normal tissues.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.